ALX Oncology to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
ALX Oncology Holdings (Nasdaq: ALXO), a clinical-stage biotechnology company focused on developing immune system-boosting cancer therapies, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. CEO Jason Lettmann will present a company overview on Wednesday, January 15, 2025, at 3:00 p.m. Pacific Time.
The presentation will be accessible via live webcast through a direct link and the Investors section of ALX Oncology's website under the Events section of the News and Events tab. A replay of the presentation will remain available for up to 30 days after the event.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, ALXO gained 3.91%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
SOUTH SAN FRANCISCO, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients’ lives, today announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. Chief Executive Officer, Jason Lettmann, will deliver a company overview presentation on Wednesday, January 15, 2025, at 3:00 p.m. Pacific Time.
A live webcast of the presentation is available by clicking the link and can also be accessed by visiting the Investors section of ALX Oncology’s website at www.alxoncology.com under the Events section of the News and Events tab. A replay of the webcast will be archived for up to 30 days following the presentation date.
About ALX Oncology
ALX Oncology (Nasdaq: ALXO) is a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients’ lives. ALX Oncology’s lead therapeutic candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy upon which the future of immuno-oncology can be built. Evorpacept is currently being evaluated across multiple ongoing clinical trials in a wide range of cancer indications. More information is available at www.alxoncology.com and on LinkedIn @ALX Oncology.
FAQ
When is ALX Oncology (ALXO) presenting at the 2025 J.P. Morgan Healthcare Conference?
How can investors watch ALX Oncology's J.P. Morgan Healthcare Conference presentation?
How long will the replay of ALXO's J.P. Morgan Healthcare Conference presentation be available?
What is the focus of ALX Oncology's presentation at the 2025 J.P. Morgan Healthcare Conference?
